Drug class
Long-acting humanised monoclonal antibody; interleukin-5 (IL-5) antagonist
Mechanism of action
Binds IL-5 with high affinity and prevents IL-5 from interacting with its receptor on eosinophils, reducing eosinophil maturation, survival and inflammatory activity. Its extended duration supports dosing every six months.
General use cases
- Add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adults and paediatric patients aged 12 years and older under the US FDA indication; not for acute bronchospasm or status asthmaticus
- Add-on therapy with intranasal corticosteroids for severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults under the EMA/Australian product indications where systemic corticosteroids and/or surgery have not provided adequate control
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
